Report #2848929

Received Jul 8, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: —
Recovered: Unknown
Vaccinated: Jun 28, 2025
Onset: Jun 28, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	UNK	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

had a dose of Shingrix 5 years ago, had another dose yesterday; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of drug dose administration interval too long in a patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (1st dose received 5 years ago). On 28-JUN-2025, the patient received the 2nd dose of Shingrix. On 28-JUN-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: had a dose of Shingrix 5 years ago, had another dose yesterday). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 29-JUN-2025 The patient received 2nd dose at longer interval than recommended which led lengthening of vaccination schedule. The reporter asked did he/she need a third dose in 2 to 4 months.